Latest news with #Ontada
Business Wire
4 days ago
- Business
- Business Wire
Atropos Health Continues Commitment to Advancements in Oncology with Addition of Key Personnel
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, the leader in generating personalized real-world evidence (RWE) from real-world clinical data, today announced key personnel and product features enhancing their Oncology solutions. The company previously announced the expansion of the Oncology MultiModal Network in the Atropos Evidence™ Network with the addition of Ontada's community oncology real-world data (RWD). In addition to the growth of the Atropos Evidence Network, Atropos Health is also adding key personnel to enhance the oncology focus: Cory D. Wiegert joins as Chief Operating Officer, bringing over 25 years of experience leading innovation and product development in enterprise software and healthcare IT including the launch of a cloud-based, AI-driven decision platform. His extensive background also includes overseeing the industry's largest dataset for value-based, specialty care at Integra Connect and leadership roles at CancerLinQ, IBM Watson Health, and Siebel Systems. Dr. Morgan Cheatham joins the Atropos Health Board of Directors as a Board Observer bringing extensive expertise as Partner and Head of Healthcare and Life Sciences for Breyer Capital, where he leads investments across various sectors, including AI. Previously at Bessemer Venture Partners, he spearheaded early-stage investments in companies like Abridge and Hinge Health. Cheatham is also pursuing a fellowship in Clinical Genetics at Harvard/Boston Children's, serves on the Editorial Team for NEJM AI and Board Director for Coalition for Health AI, and has published research on clinical AI and genetic medicine in leading journals. Jason Jones heads Data Science at Atropos Health bringing extensive experience as the former Chief Data Scientist at Health Catalyst and a Research Scientist and VP at Kaiser Permanente. His background also includes significant roles in medical informatics at Intermountain Healthcare and leadership positions at Bayer HealthCare and UnitedHealth Group. "We're investing heavily in both product and personnel when it comes to applying RWE to oncology practice and research and development," said Dr. Brigham Hyde, CEO and co-founder at Atropos Health. "Bringing on additional Oncology-specific expertise signals our further investment and commitment to advancing life saving treatments in oncology. " Along with the Ontada partnership, existing partner Norstella is now also an additional source of RWD for the Oncology MultiModal network in the Atropos Evidence Network, further enhancing the market leading federated oncology evidence network. About Atropos Health Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence. To learn more about Atropos Health, visit or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.
Business Wire
4 days ago
- Health
- Business Wire
Ontada Unveils Comprehensive Data on Social Determinants of Health and Outcomes of Early-Onset Colorectal Cancer at ASCO
BOSTON--(BUSINESS WIRE)-- Ontada ®, a leader in real-world oncology data and insights, is proud to present its latest research findings in a pivotal oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. The study, titled, "Real-world Social Determinants of Health and Outcomes of Early-onset Colorectal Cancer: An Analysis of a Large Nationally Representative US Community Oncology Network," provides critical data on the impact of social determinants on the outcomes of early-onset colorectal cancer (EO-CRC) patients, and offers one of the largest studies of EO-CRC to date. Over 104,000 patients with CRC were studied, including nearly 15,000 patients with early-onset CRC. Key Data Findings Racial and ethnic disparities: A higher burden of EO-CRC was observed among patients of Black and American Indian/Alaskan Native race and Hispanic/Latino ethnicity. Obesity as a risk factor: There was a 5% higher prevalence of obesity among patients with early-onset CRC versus average onset CRC. More advanced stage at diagnosis for EO-CRC: Patients with EO-CRC have an 11% greater likelihood of diagnosis at Stage III or IV disease as compared to average-onset disease. Poorer survival associated with advancing age: At each cancer stage, patients with EO-CRC had a longer overall survival as compared to patients with average-onset CRC, reflecting existing knowledge about cancer survival decreasing with advancing age. Importance of screening and earlier diagnosis: Among all patients with CRC, including early-onset diagnosis, disease stage at diagnosis was the strongest predictor of overall survival, reflecting the importance of earlier detection and screening programs for all. 'Understanding the complex interplay between social factors and cancer incidence and outcomes is crucial for developing effective, patient-centered care strategies, and this research underscores the importance of understanding and then intervening on social determinants of health to improve care for patients with EO-CRC,' said Jessica K. Paulus, ScD, senior director, Real-World Research, Ontada. 'Ontada's data provides a clear and compelling picture of the impact of social determinants on the outcomes of patients with EO-CRC. By leveraging our unique data emanating from the nationally representative The US Oncology Network and our measures of social determinants at scale, we can drive meaningful changes in clinical practice and policy, ultimately improving patient care and outcomes.' Study Methodology This retrospective observational cohort study examined adult CRC patients within The US Oncology Network and non-Network practices, encompassing over 2,700 community-based providers treating more than 1.4 million patients annually. All patients diagnosed with CRC between 2000 and 2024 were included; patients were categorized as EO-CRC if they were <50 years at first diagnosis and average-onset (AO)-CRC otherwise. Over 104,000 patients with CRC were studied, including nearly 15,000 patients with early-onset CRC. Patient characteristics were sourced from iKnowMed, an oncology-specific electronic health record system, and descriptively summarized. Overall Survival (OS) was assessed from diagnosis using Kaplan-Meier methods. Other Research at ASCO 2025 Ontada is showcasing its research capabilities at ASCO with 12 accepted abstracts on topics such as using large language models to extract cancer data, accelerating Phase 2 clinical development with real-world data in HER2-positive metastatic breast cancer, validating real-world event-free survival in early-stage triple negative breast cancer, analyzing outcomes of BRAF-mutated melanoma patients, and providing a descriptive epidemiology of Waldenström Macroglobulinemia. 'At Ontada, we are at the forefront of transforming cancer care through the power of real-world data and insights,' said Christine Davis, president, Ontada. 'Our extensive research at ASCO 2025 underscores our commitment to driving meaningful advancements in oncology. This research will not only highlight the critical role of real-world evidence in improving patient outcomes but also demonstrate our dedication to addressing the complex challenges faced by cancer patients and healthcare providers.' Ontada is a part of McKesson, which has an unmatched portfolio of oncology businesses and partners that provide research, insights, technologies, and services that are helping address barriers and improve cancer and specialty care. At ASCO, McKesson-supported businesses including The US Oncology Network, Ontada, and Sarah Cannon Research Institute (SCRI), are part of approximately 170 accepted abstracts and presentations. These are inclusive of oral and poster presentations, educational sessions, late-breaking studies, and early-phase studies. For a comprehensive list of Ontada abstracts and presentations, visit Ontada's ASCO 2025 Site. Additionally, visit the Ontada Booth (#35093) at the McCormick Place Convention Center from May 30 – June 3 to explore the data presented at ASCO 2025 and experience Ontada's solutions firsthand. About Ontada ® Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the core belief that precise insights – delivered exactly at the point of need – can save more patients' lives. We connect the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by all top 15 global life sciences companies. Our work helps accelerate innovation and powers the future of cancer care. For more information, visit About McKesson Oncology and Specialty Solutions It's an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care. McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through its joint venture with Sarah Cannon Research Institute. The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers. Ontada ®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care. As a leading distributor of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them. And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines.
Business Wire
5 days ago
- Business
- Business Wire
Trinity Life Sciences Expands Data Partnership Network to Revolutionize Commercialization in Community Oncology
BUSINESS WIRE)-- Trinity Life Sciences, a leader in advisory, insights and analytics for the life sciences industries, announces a strategic collaboration with Ontada, a McKesson business and leader in community oncology real-world data, clinical education and point-of-care technologies. This relationship will provide life sciences companies with real-time, actionable intelligence and critical insights to drive strategic decisions both pre- and post-product launch. Together, the alliance harnesses Trinity's innovative commercial analytics methods and expertise with Ontada's iKnowMed ®, their proprietary electronic health record (EHR) with unique, deep and multi-dimensional oncology data, to rapidly uncover novel commercial insights. These insights can be leveraged to drive smarter decisions and better outcomes, ultimately enabling a transformation in the way life sciences companies make commercial decisions. Through deep understanding of the community oncology patients and providers, the collaborative solutions: - provide more powerful patient journeys and provider segmentation, - allow for increased speed and accuracy in forecasting, - and drive enhanced customer engagement and targeting. 'Understanding community oncology presents a particular challenge for commercial teams as they work to develop strategies and deploy resources to maximize adoption of life-saving therapies,' said Leslie Orne, President and CEO of Trinity Life Sciences. 'Ontada's data, coupled with Trinity's analytical services, allows the extraction of deeper, more actionable insights and powers more impactful commercial decision-making that will help to optimize patient outcomes.' Trinity's oncology expertise and depth across areas such as forecasting, real-world analytics and primary market research (PMR) allows for distinctive, AI-enhanced approaches that provide ever-greater insight into key business questions to assess potential outcomes. Trinity offers innovative solutions built for life sciences' unique needs, scaling transformational AI and tech-enabled programs across functions with a focus on customer engagement, launch, medical affairs and GenAI. 'The need for rapid insights in cancer care has never been greater. Ontada's collaboration with Trinity demonstrates our commitment to delivering faster answers to critical questions. By connecting Trinity's robust analytics with Ontada's nuanced and unique data sets, we can provide deeper, more actionable insights for our life science partners,' said Christine Davis, President of Ontada. 'Speed is crucial not only to our life science partners but also for cancer patients, who can benefit greatly from a better understanding of precision therapies.' Ontada's real-world data provides comprehensive insights throughout the patient journey and a unique view of community cancer care. It represents data from more than 2.4 million patient records across over 80 tumor types from The US Oncology Network and Onmark practices. Ontada's iKnowMed ® is an award winning EHR used by more than 2,400 oncology community-based providers across the United States, dedicated to advancing local cancer care and better patient outcomes. To learn more about this collaboration, visit Trinity Life Sciences and Ontada (at Ontada's booth 35093) at ASCO. About Trinity Life Sciences With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits. To learn more about how Trinity is elevating the industry and driving evidence to action, visit
National Post
05-05-2025
- Health
- National Post
Ontada Illuminates the Power of its Real-World Evidence to Improve Health Outcomes for People with Cancer at ISPOR 2025
Article content Article content Article content BOSTON — Ontada ®, a McKesson business and leader in community oncology real-world data, clinical education, and point of care technologies, today announced more than 14 abstracts at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2025 Annual Meeting taking place May 13-16, 2025 in Montreal, Canada. Ontada's presence at the conference includes a podium presentation and 13 research posters. Ontada researchers will also lead a workshop on successful models for growing patient engagement in health economic outcomes research and an issue panel on the readiness of social determinants of health data. Article content 'Our extensive research portfolio underscores our commitment to driving meaningful advancements in patient care in oncology,' said Amy O'Sullivan, PhD, Senior Vice President and Chief Research Officer, Ontada. 'Our significant presence at ISPOR 2025 demonstrates the role we can play in powering important real world evidence generation evaluating the value, safety, and efficacy of cancer therapies in the real world.' Article content Highlights of Ontada's presence at ISPOR 2025 include: Article content Podium Presentation – Introduction of Distress Thermometer (DT) Screening in the US Community Oncology Setting: A Retrospective Study of Electronic Health Records (EHR) Integration: This study evaluated DT utilization following EHR implementation in 2023 across a large network of US community oncology clinics. Poster – Evolving Real-world Trends in Biomarker Testing for Bladder Cancer: A Comprehensive Retrospective Analysis from the US Community Oncology Setting (2015-2024): This study examined real-world trends in biomarker testing for BC within a US community oncology network over the past decade. Poster – Assessing the Correlation between Time to Metastatic Disease and Overall Survival in a Real-World Pan-Tumor Cohort: To understand the potential of TTMd as a proxy endpoint, this study assessed the relationship between TTMd and OS among patients with several solid tumor types in the community oncology setting. Poster – Evidence for the Cumulative Impact of Social Determinants of Health (SDOH) on Cancer Mortality: A Scoping Review: This scoping review evaluated the breadth of evidence published on the relationship between SDOH and cancer mortality, aiming to distinguish key concepts, common methodologies, and knowledge gaps. Poster – Development and Application of a Novel Framework for Clinician Stakeholder Engagement in Real-world Data (RWD) Studies: This study developed a conceptual framework for the integration of clinician stakeholder feedback into RWD investigations and report on three applied examples. Poster – Accelerating EHR Insights: NLP-Driven Data Abstraction in Gallbladder Cancer: This study utilized natural language processing (NLP) to extract TNM staging and histology data from unstructured EHR documents to improve data completeness and accuracy. Poster – Real-World Impact Of Recurrence On Overall Survival (OS) In Patients With Unresectable Locally Advanced (LA) Esophageal/Gastroesophageal Junction Cancer (EC/GEJC) Treated With Definitive Chemoradiotherapy (dCRT) In US Community Oncology Clinics: This study assessed the impact of recurrence on OS using real-world data. Poster – Use of Sensitivity Analysis to Address Potential Missing Data and Selection Bias from Linked Genomics Datasets in a Real-World Study of Patients Receiving Immune-Checkpoint Inhibitors for Metastatic Melanoma: This study investigates the use of sensitivity analysis to address such bias from a linked genomics database in patients treated with immune-checkpoint inhibitors (ICI) for metastatic melanoma. Poster – Utilizing NLP to Enhance EHR Data Abstraction Accuracy in Waldenström Macroglobulinemia: To improve data completeness and accuracy, natural language processing (NLP) was applied to extract diagnoses and dates from unstructured pathology reports for Waldenström macroglobulinemia (WM), a rare B-cell neoplasm. Poster – Validation of Real-World Pathologic Complete Response in Early Stage Triple Negative Breast Cancer: This retrospective observational study examined the concordance between rwpCR and KEYNOTE-522 trial 'chemotherapy only' arm pCR estimates. Poster – Real-World Treatment Patterns of First-Line (1L) Ibrutinib in Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL): Insights into Therapy Interruptions, Discontinuation and Next Treatment: Given the evolving treatment landscape and continued reliance on ibrutinib despite availability of newer targeted therapies, this real-world study aimed to characterize treatment patterns in CLL/SLL patients who began first-line (1L) ibrutinib-based regimens between 11/21/2019 and 7/31/2023 in The US Oncology Network. Poster – Implementation of New Real-World Data Quality Frameworks and Initiatives to Address Challenges in Oncology Electronic Health Record (EHR)-Derived Databases for Research: This study aims to summarize and implement new real-world data (RWD) quality frameworks and initiatives to improve the relevance, reliability, and external validity of oncology EHR-derived databases for research. Poster – Real-World Breast Cancer gene 1 (BRCA1) and Breast Cancer gene 2 (BRCA2) Testing Trends by Race for Patients with Metastatic Prostate Cancer (mPC) from 2015 to 2024 in the Community Oncology Setting in the United States (US): This real-world analysis evaluated BCRA1/2 testing trends by race among patients with mPC within a large network of US community practices. Poster – Validation of Real-World Recurrence-Free Survival (rwRFS) and Distant Metastasis-Free Survival(rwDMFS) Endpoints in Early-Stage Melanoma: This study applied trial emulation methods to examine the concordance between rREFS and rwDMFS estimates from the KEYNOTE-716 trial as a measure of real-world endpoint validity. Issue Panel – Are Social Determinants of Health (SDoH) Data Ready for Primetime?: This session will debate the readiness of SDoH data to inform our efforts to address health disparities in the US. Workshop – Integrating the Patient Voice: Successful Models of Continuous Engagement Science (CES) That Advance Data Science and Drug Development: This workshop will describe CES strategies to enhance trustworthiness in health economics and outcomes research (HEOR) studies among patients, the public, and other decision-maker communities. Article content For a comprehensive list of abstracts and presentations, visit Ontada's ISPOR 2025 Site. Article content Additionally, visit the Ontada Booth (#1221) at the Montreal Convention Centre from May 13-16 to explore the data presented at ISPOR 2025 and experience Ontada's solutions firsthand. Article content Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the core belief that precise insights – delivered exactly at the point of need – can save more patients' lives. We connect the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by all top 15 global life sciences companies. Our work helps accelerate innovation and powers the future of cancer care. For more information, visit Article content It's an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care. Article content McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through its joint venture, Sarah Cannon Research Institute. The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers. Ontada ®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care. As a leading distributor of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them. And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines. Article content Article content Article content Article content Contacts Article content Article content Article content
Business Wire
05-05-2025
- Health
- Business Wire
Ontada Illuminates the Power of its Real-World Evidence to Improve Health Outcomes for People with Cancer at ISPOR 2025
BOSTON--(BUSINESS WIRE)-- Ontada ®, a McKesson business and leader in community oncology real-world data, clinical education, and point of care technologies, today announced more than 14 abstracts at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2025 Annual Meeting taking place May 13-16, 2025 in Montreal, Canada. Ontada's presence at the conference includes a podium presentation and 13 research posters. Ontada researchers will also lead a workshop on successful models for growing patient engagement in health economic outcomes research and an issue panel on the readiness of social determinants of health data. 'Our extensive research portfolio underscores our commitment to driving meaningful advancements in patient care in oncology,' said Amy O'Sullivan, PhD, Senior Vice President and Chief Research Officer, Ontada. 'Our significant presence at ISPOR 2025 demonstrates the role we can play in powering important real world evidence generation evaluating the value, safety, and efficacy of cancer therapies in the real world.' Highlights of Ontada's presence at ISPOR 2025 include: Podium Presentation - Introduction of Distress Thermometer (DT) Screening in the US Community Oncology Setting: A Retrospective Study of Electronic Health Records (EHR) Integration: This study evaluated DT utilization following EHR implementation in 2023 across a large network of US community oncology clinics. Poster - Evolving Real-world Trends in Biomarker Testing for Bladder Cancer: A Comprehensive Retrospective Analysis from the US Community Oncology Setting (2015-2024): This study examined real-world trends in biomarker testing for BC within a US community oncology network over the past decade. Poster - Assessing the Correlation between Time to Metastatic Disease and Overall Survival in a Real-World Pan-Tumor Cohort: To understand the potential of TTMd as a proxy endpoint, this study assessed the relationship between TTMd and OS among patients with several solid tumor types in the community oncology setting. Poster - Evidence for the Cumulative Impact of Social Determinants of Health (SDOH) on Cancer Mortality: A Scoping Review: This scoping review evaluated the breadth of evidence published on the relationship between SDOH and cancer mortality, aiming to distinguish key concepts, common methodologies, and knowledge gaps. Poster - Development and Application of a Novel Framework for Clinician Stakeholder Engagement in Real-world Data (RWD) Studies: This study developed a conceptual framework for the integration of clinician stakeholder feedback into RWD investigations and report on three applied examples. Poster - Accelerating EHR Insights: NLP-Driven Data Abstraction in Gallbladder Cancer: This study utilized natural language processing (NLP) to extract TNM staging and histology data from unstructured EHR documents to improve data completeness and accuracy. Poster - Real-World Impact Of Recurrence On Overall Survival (OS) In Patients With Unresectable Locally Advanced (LA) Esophageal/Gastroesophageal Junction Cancer (EC/GEJC) Treated With Definitive Chemoradiotherapy (dCRT) In US Community Oncology Clinics: This study assessed the impact of recurrence on OS using real-world data. Poster - Use of Sensitivity Analysis to Address Potential Missing Data and Selection Bias from Linked Genomics Datasets in a Real-World Study of Patients Receiving Immune-Checkpoint Inhibitors for Metastatic Melanoma: This study investigates the use of sensitivity analysis to address such bias from a linked genomics database in patients treated with immune-checkpoint inhibitors (ICI) for metastatic melanoma. Poster - Utilizing NLP to Enhance EHR Data Abstraction Accuracy in Waldenström Macroglobulinemia: To improve data completeness and accuracy, natural language processing (NLP) was applied to extract diagnoses and dates from unstructured pathology reports for Waldenström macroglobulinemia (WM), a rare B-cell neoplasm. Poster - Validation of Real-World Pathologic Complete Response in Early Stage Triple Negative Breast Cancer: This retrospective observational study examined the concordance between rwpCR and KEYNOTE-522 trial 'chemotherapy only' arm pCR estimates. Poster - Real-World Treatment Patterns of First-Line (1L) Ibrutinib in Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL): Insights into Therapy Interruptions, Discontinuation and Next Treatment: Given the evolving treatment landscape and continued reliance on ibrutinib despite availability of newer targeted therapies, this real-world study aimed to characterize treatment patterns in CLL/SLL patients who began first-line (1L) ibrutinib-based regimens between 11/21/2019 and 7/31/2023 in The US Oncology Network. Poster - : This study aims to summarize and implement new real-world data (RWD) quality frameworks and initiatives to improve the relevance, reliability, and external validity of oncology EHR-derived databases for research. Poster - Real-World Breast Cancer gene 1 (BRCA1) and Breast Cancer gene 2 (BRCA2) Testing Trends by Race for Patients with Metastatic Prostate Cancer (mPC) from 2015 to 2024 in the Community Oncology Setting in the United States (US): This real-world analysis evaluated BCRA1/2 testing trends by race among patients with mPC within a large network of US community practices. Poster - Validation of Real-World Recurrence-Free Survival (rwRFS) and Distant Metastasis-Free Survival(rwDMFS) Endpoints in Early-Stage Melanoma: This study applied trial emulation methods to examine the concordance between rREFS and rwDMFS estimates from the KEYNOTE-716 trial as a measure of real-world endpoint validity. Issue Panel - Are Social Determinants of Health (SDoH) Data Ready for Primetime?: This session will debate the readiness of SDoH data to inform our efforts to address health disparities in the US. Workshop - Integrating the Patient Voice: Successful Models of Continuous Engagement Science (CES) That Advance Data Science and Drug Development: This workshop will describe CES strategies to enhance trustworthiness in health economics and outcomes research (HEOR) studies among patients, the public, and other decision-maker communities. For a comprehensive list of abstracts and presentations, visit Ontada's ISPOR 2025 Site. Additionally, visit the Ontada Booth (#1221) at the Montreal Convention Centre from May 13-16 to explore the data presented at ISPOR 2025 and experience Ontada's solutions firsthand. About Ontada ® Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the core belief that precise insights – delivered exactly at the point of need – can save more patients' lives. We connect the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by all top 15 global life sciences companies. Our work helps accelerate innovation and powers the future of cancer care. For more information, visit About McKesson Oncology and Specialty Solutions It's an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care. McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through its joint venture, Sarah Cannon Research Institute. The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers. Ontada ®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care. As a leading distributor of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them. And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines.
